Longeveron Inc. (LGVN) stock
Close on Nov 17, 2026Market cap $67.27MP/E –Yield –
Longeveron Inc. saw revenue fall 42.7% to $1.19M over the twelve months to Jun 30, 2026. Free cash flow was -$20.53M. At the latest close the market valued the company at $67.27M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $67.27M
- P/E ratio
- –
- Price to sales
- 56.67
- Price to book
- 6.47
- Dividend yield
- –
- Free cash flow yield
- -30.52%
Fundamentals
- Revenue
- $1.19M
- Net income
- -$23.47M
- EPS, diluted
- -$0.77
- Free cash flow
- -$20.53M
- Book value per share
- $0.33
- Diluted shares
- 31M
Trading
- Previous close
- $2.14
- Open
- $2.23
- Day's range
- $2.04 – $2.23
- Volume
- 28,298
- Average volume (20 days)
- 100,297
- 52-week range
- $1.31 – $12.30
- RSI (14 days)
- 46.2
- Volatility (1 year)
- 133.4%
- Relative volume
- 0.30×
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | LGVN | S&P 500 | Difference | LGVN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +51.8% | -4.0% | +55.8 pts | ||
| 3 months | -74.3% | -5.0% | −69.3 pts | ||
| Year to date | -58.3% | +8.2% | −66.5 pts | ||
| 1 year | -67.5% | +11.2% | −78.7 pts | ||
| 3 years | -98.9% | +68.5% | −167.4 pts | -77.7% | +19.0% |
| 5 years | -99.3% | +67.3% | −166.6 pts | -62.7% | +10.8% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Longeveron filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Results
- Results
About Longeveron
Pharmaceutical Preparations
Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for unmet medical conditions. Its primary investigational product candidate is laromestrocel, an allogeneic cell therapy designed to promote tissue repair and reduce inflammation. The firm focuses on advancing treatments across several therapeutic indications, including hypoplastic left heart syndrome, Alzheimer’s disease, aging-related frailty, and pediatric dilated cardiomyopathy. Its customer and user base includes clinical trial participants, patients, and third-party partners seeking contract development and manufacturing services.
Company profile, executives and historyLongeveron stock: common questions
What is Longeveron's stock price?
LGVN closed at $2.11 on Nov 17, 2026, down 1.40% on the day. Over the past 52 weeks it traded between $1.31 and $12.30.
What is Longeveron's market cap?
Longeveron was worth $67.27M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is LGVN's P/E ratio?
Longeveron lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.77), so it has no meaningful P/E ratio.
How much revenue does Longeveron make?
Longeveron reported revenue of $1.19M for the twelve months to Jun 30, 2026, down 42.7% from a year earlier.
Does Longeveron pay a dividend?
No. Longeveron has not paid a cash dividend over the last twelve months.
How has LGVN stock performed over the past year?
Including dividends, LGVN returned -67.5% over the past year, against +11.2% for the S&P 500.
How many LGVN shares are sold short?
0M shares were sold short at the latest FINRA report, 0.88% of the float, or 2.2 days of average trading volume.
Who are Longeveron's competitors?
Companies most similar to Longeveron by business, industry and size include IGC, RNAC, MNOV, RFL, NGNE.
See a number that looks wrong?